口服司美格鲁肽联合胰岛素治疗2型糖尿病的疗效与安全性
PIONEER 8试验为52周双盲随机对照研究,纳入胰岛素联合或不联合二甲双胍血糖控制不佳的2型糖尿病患者,随机接受口服司美格鲁肽3、7、14 mg或安慰剂。第26周时,口服司美格鲁肽各剂量在降低HbA1c和体重方面均优于安慰剂,安全性与其它GLP-1受体激动剂一致。
要点
- 口服司美格鲁肽各剂量降HbA1c和体重均优于安慰剂,且呈剂量依赖。
- 最常见不良事件为恶心,多为轻中度。
- 安全性特征与其它GLP-1受体激动剂一致。
核心结论
- 在胰岛素联合或不联合二甲双胍治疗的2型糖尿病患者中,口服司美格鲁肽降HbA1c和体重优于安慰剂。
- 口服司美格鲁肽安全性与其它胰高血糖素样肽1受体激动剂一致。
研究设计与样本
- 52周双盲随机对照试验,患者随机分为口服司美格鲁肽3 mg组(N = 184)、7 mg组(N = 182)、14 mg组(N = 181)或安慰剂组(N = 184)。
- 主要终点为基线至第26周HbA1c变化,确证性次要终点为体重变化。
主要发现
- 第26周HbA1c降幅(治疗策略估计目标)估计治疗差异:3 mg为-0.5%(95% CI -0.7, -0.3),7 mg为-0.9%(-1.1, -0.7),14 mg为-1.2%(-1.4, -1.0),均P < 0.001。
- 第26周体重降幅(治疗策略估计目标)估计治疗差异:3 mg为-0.9 kg(95% CI -1.8, -0.0),P = 0.0392;7 mg为-2.0 kg(-3.0, -1.0),P ≤ 0.0001;14 mg为-3.3 kg(-4.2, -2.3),P ≤ 0.0001。
- 第26周和第52周两个估计目标下,口服司美格鲁肽较安慰剂的HbA1c和体重降幅均显著更大且呈剂量依赖。
- 口服司美格鲁肽最常见不良事件为恶心,发生率11.4-23.2%,安慰剂为7.1%,多为轻中度。
临床怎么用
- 对胰岛素联合或不联合二甲双胍控制不佳的2型糖尿病患者,可考虑加用口服司美格鲁肽以改善血糖和体重。
- 用药时需关注恶心等胃肠道不良事件,多为轻中度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS: Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment difference [ETD] -0.5% [95% CI -0.7, -0.3], -0.9% [-1.1, -0.7], and -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD -0.9 kg [95% CI -1.8, -0.0], -2.0 kg [-3.0, -1.0], and -3.3 kg [-4.2, -2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4-23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS: Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.
引用
- Zinman B, Aroda VR, Buse JB, et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019. PMID: 31530667. doi:10.2337/dc19-0898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。